Article Details

Zenas BioPharma Gains Outperform Rating From Analyst As Key Autoimmune Trials Progress

Retrieved on: 2025-03-21 04:52:06

Tags for this article:

Click the tags to see associated articles and topics

Zenas BioPharma Gains Outperform Rating From Analyst As Key Autoimmune Trials Progress. View article details on hiswai:

Excerpt

Wedbush initiates coverage on Zenas BioPharma, citing strong potential for obexelimab in autoimmune diseases, with key clinical data expected in ...

Article found on: www.benzinga.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo